Agluna® Set for Acceleration into the Dental Implant Sector

16 January 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to have been awarded a Phase 1 grant from the European Commission’s Horizon 2020 SME Instrument, managed by EASME (the European Unions’ Executive Agency for Small and Medium Sized Enterprises).

The grant is awarded in support of Project ADA - Accelerating the Dissemination of Agluna®, a clinically proven innovative silver ion based anti-microbial surface technology, from the orthopaedic sector into the dental implant sector.

Agluna® has already demonstrated a significant reduction in the incidence of post-operative infection in clinical use within the EU limb salvage market, and is being actively commercialised within the global orthopaedic market. Accentus now plans to confirm the commercial application of the technology to dental implants. The first phase will cover business planning and regulatory aspects, in anticipation of Phase 2 of the project in which Agluna® will be piloted on a dental implant product that is designed, manufactured and clinically tested in a human proof of concept study.

James Armstrong, Business Development Manager, said: “Implant related infections are associated with the formation of biofilm on the surface of implanted devices. This is a global problem with socio-economic costs recognised across a range of medical device sectors. The dental implant sector is actively searching for solutions to the problem of post-operative implant infection and peri-implantitis. With growing concern about antibiotic resistant bacterial strains, the subsequent expected outcome following this project is for Agluna® to become commercialised in EU/global markets as a differentiated, cost effective and clinically proven technology utilising silver ions, a well-known biocide with very limited reported bacterial resistance.”

Dr Philip Agg, CEO, said: “I am delighted that the European Commission has selected
Accentus Medical for this Phase 1 grant award. We are excited by the potential opportunities for commercialising Agluna® within the global dental implant market, and look forward to bringing the technology to clinical end users in this high-growth medical device sector.”


For further information, please contact:
Lynne Trowbridge
T: +44 (0)20 7866 7855

About Agluna®
Agluna® harnesses the anti-microbial properties of silver ions in preventing device related infection. The technology is an electrochemical process involving high voltage anodisation of the titanium implant in phosphoric acid, followed by incorporation of silver ions from an aqueous solution. Agluna® is protected by several patent families registered in major global territories.

About Accentus Medical
Accentus Medical is a global leader in delivery of innovative, silver-based anti-microbial surface treatments and biocompatible coatings on implantable medical devices. The company combines a long history of expertise in surface technologies, with dedicated research and development of new technologies for the medical device industry. Based at the historic Harwell Oxford campus, Accentus Medical has provided expertise in surface technologies to the orthopaedic device industry since the 1970s, serving major orthopaedic and medical device manufacturers worldwide.

The company has two principal technology platforms: Agluna® silver anti-microbial surface treatment for prevention and control of post-operative infection, and Acusure® plasma spray coating for improving biocompatibility and durability of implants. These technologies are supplied to customers at Accentus Medical’s ISO13485:2012 and ISO9001:2008 accredited facility. Accentus Medical is also very well known for the medical device testing programmes offered by its in-house test laboratories. Manufacturers have been utilising test results provided by the company for many years as part of device homologation files all over the world.

For further information, please visit:

Download PDF

Contact Us

T: +44 (0)1235 434 320
F: +44 (0)1235 434 329